

NOVOGEN

## Boardroom Radio eConference July 2009

- Impact of the GFC
  - Biotech
    - Funding
    - M&A
  - Company
    - Financial position
    - Expenditure reductions
    - Programs
    - Staff


## Biotech

- Absence of IPOs / follow-ons
- Cash for going concern
- Large Pharma appetite
- M&A
- Funding window – terms
  - 2009 YTD (19/6/09) Follow-on transactions priced at an average discount of 14.2% to filing for issuers of all sizes\*
  - 2009 YTD (19/6/09) average warrant coverage on Registered Direct Offerings 61.5%\*

\*Oppenheimer & Co Inc release 24.6.09

## Company specific

- Program rationalisation
  - Near term
  - Focus oncology
  - Postpone anti-inflammatory/cardiovascular
- Expenditure
  - savings in projects and staff reductions
    - Chemistry – near term
    - Manufacturing - outsourcing
    - Biology – near term
  - Executive and Board 20% remuneration cuts
  - Property rationalisation



## ● Financial Position

At Dec 31 2008

Group Cash A\$ 44M

- Novogen
- Marshall Edwards
- Glycotex

- \$10m raised into the Group in July '08 prior to height of GFC.

## ● Staff

Currently 46 (62 in 2008) people world wide directly employed – many others contract / consult / collaborate.

- 24(37) in R & D
  - Chemistry and Biology
  - QA
  - Clinical
  - Drug production
- 11(13) in OTC
  - 2 (3) Overseas
  - 9(10) Aust sales and marketing
- 11(12) in Admin
  - 6(7) Finance
  - 1 IT
  - 4 Corporate

## ● Patent Portfolio

- **37** patent families
- **16** new patents granted last year and **16** prior year
- Total of **107** patents now granted world wide – up from **94** to Oct 2008.
- Over **200** patent applications now in the system
- Expanding portfolio

## ● Novogen Shareholding Analysis

- ASX shareholding..... 52%
  - NASDAQ ADRs..... 48%
  - Of the 52% on the ASX, at least 15% held by US interests
  - so plus ADRs, .....
- ...majority of Novogen ....around 65% is US held

## ● Research and Development

- Oncology : pre-clinical compounds and the Marshall Edwards' program
- Cardiovascular : pre-clinical compounds, NV-27, and phase I clinical with trans-NV-04
- Anti-inflammatory: pre-clinical compounds, FAIMS and phase I clinical with NV-52
- Wound healing : the Glycotex clinical program with Glyc-101.

# NOVOGEN

- New Promensil and Trinovin products and international expansion – in 19 countries, expanding by another 2-4 countries in current year.



- Marshall Edwards Licensing

- The oncology program in Marshall Edwards Inc - designed for out-licensing.
- Phenoxodiol discussions during the phase III trial now awaiting data due at end of 2009
- Co-ordination of the program by JPMorgan of New York – range from licensing to equity acquisition
- Triphendiol outreach initiated
- NV-128 planned for in-licence

# NOVOGEN

	Preclinical	Phase I	Phase II	Phase III	Target Indication
<b>Cardiovascular</b>					
<i>trans</i> -NV-04	→				Anti-atherosclerotic, peripheral vascular dilatation
NV-27	→				
<b>Anti-inflammatory</b>					
NV-07 $\alpha$	→				Anti-ageing
NV-52	→				Inflammatory bowel disease
FAIM	→				Inflammation/pain management
<b>Oncology</b>					
Phenoxodiol	→				Ovarian, prostate, cervical, cancers
Triphendiol-196	→				Cholangiocarcinoma, pancreatic cancer
NV-143	→				Melanoma
NV-128, etc	→				Lung, breast, other cancer
<b>Wound healing</b>					
Glyc-101	→				Wound management

NOVOGEN